Weighted Average Number of Shares Outstanding, Basic of Verve Therapeutics, Inc. from 31 Dec 2020 to 31 Mar 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Verve Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2020 to 31 Mar 2025.
  • Verve Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Mar 2025 was 88,795,827, a 6.8% increase year-over-year.
  • Verve Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 84,722,277, a 32% increase from 2023.
  • Verve Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 64,175,137, a 19% increase from 2022.
  • Verve Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 54,023,653, a 101% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Verve Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 88,795,827 +5,662,867 +6.8% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 84,722,277 +20,547,140 +32% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 84,632,952 +21,421,103 +34% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 84,226,523 +22,272,531 +36% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 83,132,960 +21,345,557 +35% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 64,175,137 +10,151,484 +19% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 63,211,849 +6,004,724 +10% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 61,953,992 +13,279,119 +27% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 61,787,403 +13,216,189 +27% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 54,023,653 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 57,207,125 +9,214,352 +19% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 48,674,873 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 48,571,214 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q3 2021 47,992,773 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3

Verve Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 84,722,277 +20,547,140 +32% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 64,175,137 +10,151,484 +19% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 54,023,653 +27,151,617 +101% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 26,872,036 +24,621,943 +1094% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 2,250,093 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.